{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:10:51Z","timestamp":1761901851951,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.msard.2022.103511","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T05:12:14Z","timestamp":1641791534000},"page":"103511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Low vitamin D levels do not predict risk of autoimmune disease following alemtuzumab treatment for multiple sclerosis"],"prefix":"10.1016","volume":"59","author":[{"given":"Simon","family":"Arnett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia Jimenez","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Downing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Boggild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon A","family":"Broadley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2022.103511_bib0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12016-011-8255-1","article-title":"Hypovitaminosis D as predisposing factor for atrophic type A gastritis: a case-control study and review of the literature on the interaction of Vitamin D with the immune system","volume":"42","author":"Antico","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.msard.2022.103511_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2022.103511_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.msard.2022.103511_bib0040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2022.103511_bib0027","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/eji.200535075","article-title":"Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis","volume":"35","author":"Cox","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.msard.2022.103511_bib0008","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.msard.2022.103511_bib0010","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1182\/blood-2011-08-371138","article-title":"A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis","volume":"118","author":"Cuker","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.msard.2022.103511_bib0023","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13760-018-0883-2","article-title":"Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management","volume":"118","author":"Decallonne","year":"2018","journal-title":"Acta Neurol. Belg."},{"issue":"2","key":"10.1016\/j.msard.2022.103511_bib0014","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13760-018-0922-z","article-title":"Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumab","volume":"118","author":"El Sankari","year":"2018","journal-title":"Acta Neurol. Belg."},{"issue":"3","key":"10.1016\/j.msard.2022.103511_bib0032","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.diabres.2014.12.008","article-title":"Lower serum 25 (OH) D concentrations in type 1 diabetes: a meta-analysis","volume":"108","author":"Feng","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.msard.2022.103511_bib0037","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2147\/TCRM.S188941","article-title":"Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis","volume":"15","author":"Goischke","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"issue":"8625","key":"10.1016\/j.msard.2022.103511_bib0004","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(88)90588-0","article-title":"Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H","volume":"2","author":"Hale","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2022.103511_bib0021","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.msard.2018.10.015","article-title":"Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration","volume":"27","author":"Hoffman","year":"2019","journal-title":"Multiple Scler. Related Disord."},{"issue":"11","key":"10.1016\/j.msard.2022.103511_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102392","article-title":"Vitamin D status in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis","volume":"18","author":"Islam","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.msard.2022.103511_bib0025","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.msard.2022.103511_bib0034","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jbspin.2010.02.043","article-title":"High frequency of vitamin D insufficiency in primary antiphospolipid syndrome","volume":"77","author":"Klack","year":"2010","journal-title":"Joint Bone Spine"},{"issue":"11","key":"10.1016\/j.msard.2022.103511_bib0038","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2022.103511_bib0028","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.bbmt.2016.04.005","article-title":"Immune-mediated complications after hematopoietic stem cell transplantation","volume":"22","author":"Li","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.msard.2022.103511_bib0030","first-page":"827","article-title":"Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: a meta-analysis","volume":"34","author":"Lee","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.msard.2022.103511_bib0003","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"J. Am. Med. Ass."},{"issue":"10","key":"10.1016\/j.msard.2022.103511_bib0017","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1007\/s00415-014-7448-y","article-title":"First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS","volume":"261","author":"Malmestrom","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.103511_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-223016","article-title":"Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis","author":"McCaughan","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.msard.2022.103511_bib0002","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1212\/CON.0000000000000725","article-title":"Multiple sclerosis risk factors and pathogenesis","volume":"25","author":"Nourbakhsh","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.msard.2022.103511_bib0016","article-title":"Adult-onset still disease as a novel autoimmune complication of alemtuzumab therapy: a case report and review of alemtuzumab-associated autoimmune disease","author":"Narayan","year":"2020","journal-title":"J. Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.msard.2022.103511_bib0036","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jaad.2012.01.040","article-title":"Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study","volume":"67","author":"Orgaz-Molina","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.msard.2022.103511_bib0033","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nut.2017.10.021","article-title":"High-dose vitamin D in Addison's disease regulates T-cells and monocytes: a pilot trial","volume":"49","author":"Penna-Martinez","year":"2018","journal-title":"Nutrition"},{"issue":"9","key":"10.1016\/j.msard.2022.103511_bib0011","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/1352458519841829","article-title":"Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis","volume":"25","author":"Phelps","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103511_bib0012","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006648","article-title":"Vitiligo after alemtuzumab treatment: secondary autoimmunity is not all about B cells","author":"Ruck","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2022.103511_bib0007","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.3390\/ijms160714669","article-title":"Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis\u2013report of two cases","volume":"16","author":"Rau","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2022.103511_bib0015","article-title":"Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: a case report","volume":"40","author":"Romero","year":"2020","journal-title":"Multiple Scler. Related Disord."},{"issue":"2","key":"10.1016\/j.msard.2022.103511_bib0024","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41433-018-0282-1","article-title":"Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series","volume":"33","author":"Roos","year":"2019","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.msard.2022.103511_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102492","article-title":"Immunological consequences of \"immune reconstitution therapy\" in multiple sclerosis: a systematic review","volume":"19","author":"Sellner","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"9","key":"10.1016\/j.msard.2022.103511_bib0001","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1093\/brain\/awaa145","article-title":"The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history","volume":"143","author":"Sorensen","year":"2020","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2022.103511_bib0009","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40618-019-01105-7","article-title":"Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis","volume":"43","author":"Scappaticcio","year":"2020","journal-title":"J. Endocrinol. Invest."},{"issue":"10","key":"10.1016\/j.msard.2022.103511_bib0022","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1161\/01.STR.0000181772.78492.07","article-title":"Thyroid diseases and cerebrovascular disease","volume":"36","author":"Squizzato","year":"2005","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.msard.2022.103511_bib0039","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00415-006-0315-8","article-title":"Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia","volume":"254","author":"van der Mei","year":"2007","journal-title":"J. Neurol."},{"issue":"13","key":"10.1016\/j.msard.2022.103511_bib0018","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1177\/1352458518790391","article-title":"Sarcoidosis following alemtuzumab treatment for multiple sclerosis","volume":"24","author":"Willis","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103511_bib0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.msard.2018.04.002","article-title":"Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - a non-infectious cause of breathlessness","volume":"22","author":"Whiteside","year":"2018","journal-title":"Multiple Scler. Related Disord."},{"issue":"5","key":"10.1016\/j.msard.2022.103511_bib0029","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.3390\/nu7053813","article-title":"Vitamin D and Graves' disease: a meta-analysis update","volume":"7","author":"Xu","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.msard.2022.103511_bib0013","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fneur.2017.00569","article-title":"Alopecia universalis following alemtuzumab treatment in multiple sclerosis: a barely recognized manifestation of secondary autoimmunity-report of a case and review of the literature","volume":"8","author":"Zimmermann","year":"2017","journal-title":"Front. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822000268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822000268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:00:08Z","timestamp":1761901208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822000268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":40,"alternative-id":["S2211034822000268"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103511","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low vitamin D levels do not predict risk of autoimmune disease following alemtuzumab treatment for multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103511"}}